This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of 18F FLT signal uptake abnormalities with clinical pathology reports for determining the evidence of hematopoietic disease.
Timeframe: day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment
A proportion of 18F FLT uptake in a standard region of interest in marrow to objectively identify disease status in patient with hematopoietic cancers.
Timeframe: day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment
Mean differences of 18F FLT uptake to determine extramedullary disease.
Timeframe: day -7 to 10 days pre-treatment and +28 (+/- 3 days) post-treatment